The management of dyslipidemia after myocardial infarction (MI) is an important aspect of post-myocardial infarction care. However, acute changes in the lipid profile immediately following myocardial infarction have resulted in uncertainty regarding the clinical utility of lipid levels assessed during hospitalization for MI. We studied the effect of the timing of plasma lipid assessment among 294 patients who presented with MI to determine whether the differences between the serum lipid values in-hospital when compared with post-discharge values (generally 2-3 months after MI) would have a substantial impact on the decision to initiate lipid-lowering therapy. We found that the mean total and LDL cholesterol levels were significantly lower in-hospital when compared with generally 2-3 months later. However, patients whose lipids were measured within 48 h of presentation did not have significantly different values compared with generally 2-3 months post-discharge. Moreover, despite slightly lower in-hospital levels, 83.7% of patients were above the National Cholesterol Education Program target LDL for secondary prevention and 57.6% met the criteria for drug therapy based on in-hospital assessment. Total and LDL cholesterol levels fall modestly after an acute MI; however, from a clinical perspective, in-hospital levels can be used to guide decisions regarding lipid-lowering therapy which can begin in the immediate post-MI setting. In-hospital levels approximate post-MI levels, particularly if drawn within 48 h of presentation. All patients with acute myocardial infarction should have complete lipid profiles measured prior to discharge.
Introduction
The treatment of dyslipidemia after myocardial infarction (MI) has become routine in post-MI care. The guidelines provided by the National Cholesterol Education Program (NCEP) Expert Panel in 1993 have assisted clinicians in deciding whether to institute dietary or pharmacologic lipid-lowering therapy for both primary and secondary prevention of coronary heart disease (CHD). 1 In the secondary prevention of CHD, it is clear that aggressive lipid lowering is beneficial, especially in the post-MI setting, because these patients are at the highest risk for future cardiac events. In this group, the NCEP recommends dietary therapy for individuals with low-density lipoprotein (LDL) over 100 mg/dl, and pharmacologic therapy for those with LDL over 130 mg/dl, with a target LDL of less than 100 mg/dl. There has been some reluctance to use lipid levels obtained in the setting of an acute MI because they may not reflect a patient's true lipid profile. Many authors have documented acute changes in the lipid profile immediately following infarction, [2] [3] [4] [5] [6] [7] suggesting that serum lipids drawn at this time would differ from pre-and post-MI levels. This has led some to defer measurement of lipids and thus initiation of drug thearpy until weeks or months after an MI. Among 294 patients who had suffered a first MI, we compared the serum lipid profiles drawn during hospitalization with those drawn on the same patients generally 2-3 months later to determine if acute changes in the lipid profile during infarction would have an impact on the decision to start lipid-lowering therapy based on the most recent NCEP guidelines.
Methods
The Boston Area Health Study was a case-control study designed to evaluate the inter-relationships of a number of risk factors for myocardial infarction. Methods have been previously described. 8 Briefly, the study population consisted of white men and women, less than 76 years of age, residing in the Boston area, with no prior history of myocardial infarction or angina pectoris, and who had no symptoms more than 24 h prior to presentation. MI cases were identified by review of all admissions to the coronary care and other intensive care units of six hospitals in the Boston area (Emerson, Framingham-Union, Leonard Morse, Mount Auburn, Newton-Wellesley, and Waltham). Those persons with a non-fatal myocardial infarction confirmed by evidence of creatine kinase rise were considered potential cases. For each eligible and willing MI case a control was selected, matched on the basis of age within 5 years, sex and area of residence. A total of 340 case-control pairs were enrolled in the study, representing participation rates of approximately 84% among eligible cases and 60% among controls. Analyses for this paper were confined to the MI cases.
Cases were interviewed in their homes approximately 2-3 months after their discharge from the hospital. Information was obtained on a wide variety of coronary risk factors, including demographic variables (age and gender), medical history (diabetes, hypertension, etc.), family history of premature (before age 60) myocardial infarction, and behavioral factors (cigarette smoking and alcohol consumption).
A fasting blood specimen was collected from each of the cases during admission for myocardial infarction. Time from presentation with symptoms of MI to blood collection was recorded. A second fasting sample was obtained at the time of the home interview, generally 2-3 months following the MI. Both in-hospital and post-discharge blood samples were obtained for a total of 294 MI cases. The time between presentation and the collection of the hospital blood sample was available for 271 cases, and median time was 20.5 h with 61% collected within 24 h. The median time interval between collection of the in-hospital and postdischarge sample was 10.6 weeks, with a range of 3-35.9 weeks. However, the vast majority of patients had a time interval in the range of 8-12 weeks. These specimens were analyzed for total cholesterol, LDL-, high-density lipoprotein (HDL)-, HDL2-, HDL3-and very-low-density lipoprotein (VLDL)-cholesterol, as well as triglycerides. Data were collected in 1983, prior to the NCEP guidelines and widespread use of lipid-lowering drugs. It is therefore unlikely that intervention following MI would have had a substantial impact on cholesterol levels.
The fasting blood specimens were drawn into 1.0% EDTA, and plasma was obtained by centrifugation at 3000 rpm for 30 min at 4°C. The Lipid Research Clinic methods were used to determine HDL-, LDL-, VLDL-cholesterol and triglyceride levels. [9] [10] [11] Total cholesterol and HDL cholesterol values were standardized with the lipid standardization program of the Centers for Disease Control, Atlanta, Georgia. Subfractions of HDL-cholesterol were determined by the dextran sulfate precipitation procedure. 12, 13 We first compared the known coronary risk factors and lipid levels between cases and controls to ensure that the cases of myocardial infarction represented a typical case series against which the remaining analyses would be conducted. For each lipid, the values obtained in-hospital were compared to the post-discharge value by a paired t-test. For triglycerides, which are skewed towards higher values, a logarithmic transformation was used to achieve a normal distribution and allow for the use of parametric tests. The in-hospital values were also compared to post-discharge values according to time between presentation with symptoms of MI and the in-hospital blood collection using a paired t-test, again with logarithmic transformation of triglyceride values. The percentages of patients with LDL levels above the treatment thresholds, as outlined by the Vascular Medicine 1999; 4: 227-231 1993 NCEP guidelines, were determined for both in-hospital and post-discharge samples. The percentages of patients with LDL levels above the NCEP thresholds in-hospital and post-discharge were also analyzed according to the time between presentation with symptoms and collection of the in-hospital blood sample. Table 1 shows the characteristics of the MI patients in contrast with those of the controls. A total of 78% of the cohort was male. As would be expected, the prevalence of major known coronary risk factors among cases was greater than controls. Table 2 shows the mean lipid levels from blood samples in-hospital compared with those from samples generally 2-3 months post-discharge among the 294 MI cases for whom both in-hospital and post-discharge levels were available. For total cholesterol, LDL, triglycerides, and VLDL, the mean values in-hospital were significantly lower. Total HDL and HDL3 levels were higher than those obtained post-discharge and HDL2 was unchanged. For total cholesterol, the mean in-hospital level was 10.8 mg/dl or 4.8% lower than the post-discharge level (p Ͻ 0.001). For LDL, the difference between the in-hospital and post-discharge means was 4.0 mg/dl or 2.8% lower (p = 0.04). For VLDL and triglycerides, the differences were 7.1 mg/dl or 15.8% lower and 35.7 mg/dl or 19.4% lower (p Ͻ 0.001). For HDL, the in-hospital level was 1.7 mg/dl or 4.6% higher than the post-discharge level (p Ͻ 0.002). Similarly, for HDL3, the difference between the in-hospital and post-discharge means was 1.8 mg/dl or 7.0% higher (p Ͻ 0.001). For HDL2, in-hospital and post-discharge values were virtually identical. Table 3 shows the difference between in-hospital and post-discharge mean lipid levels according to the time interval from presentation with symptoms of MI to the collection of the in-hospital sample. For total cholesterol, in-hospital levels tended to be slightly lower than postdischarge levels if the samples were drawn within the first 24 h (−3.2%) or from 24 to 48 h (−1.9%) after presentation; however, they were substantially lower than the postdischarge levels if drawn from 48 to 72 h (−13.6%) or more than 72 h (−9.3%) after presentation to the hospital. Similarly, compared with post-discharge levels, LDL cholesterol was significantly lower only if the in-hospital sample was drawn 48-72 h (−17.9%) or more than 72 h (−9.1%) after Table 3 Comparison of mean in-hospital (IH) and post-discharge (PD) lipid levels according to time between presentation of symptoms and collection of in-hospital blood.
Results
Ͻ24 h (n = 165) 24-48 h (n = 43) Table 4 , the percentages of all cases with LDL cholesterol above the NCEP thresholds for dietary (LDL Ͼ100 mg/dl) and drug therapy (LDL Ͼ130 mg/dl) are presented. When measured in-hospital, 83.7% of cases met the NCEP guidelines for dietary therapy compared with 86.6% generally 2-3 months after the MI, and 57.6% of cases met the NCEP guidelines for pharmacotherapy compared with 61.5% post-discharge, respectively. There was no material difference in the percentage of patients with LDL over the NCEP thresholds when measured in-hospital compared with post-discharge if the blood was drawn within 48 h of the onset of symptoms; however, compared with post-MI assessment, considerably fewer subjects met the criteria for non-pharmacologic (77.4% versus 88.9%) and drug intervention (50.0% versus 68.3%) if lipids were measured more than 48 h after presentation.
Discussion
We found that among patients admitted to the hospital with a confirmed MI, in-hospital and post-discharge (after generally 2-3 months) total and LDL cholesterol levels were not substantially different if the in-hospital levels were drawn within 48 h of admission. LDL levels drawn in-hospital, particularly within 48 h of the presentation, were a useful guide for the need for lipid-lowering therapy based on secondary prevention treatment thresholds provided by the NCEP. Moreover, approximately half of the patients with LDL measured in-hospital (even if it were measured after 48 h) had LDL levels warranting pharmacologic treatment based on NCEP guidelines and more than 80% of patients had LDL levels warranting at least lifestyle intervention. Although guidelines suggest dietary therapy for those with an LDL level between 100 and 130 mg/dl, many lipidologists today will also begin treatment at that level. Our finding that an in-hospital LDL Ͼ100 mg/dl was a useful guide for subsequent treatment therefore applies not only to dietary therapy but also to the initiation of drug therapy. Our findings of differences between in-hospital and postVascular Medicine 1999; 4: 227-231 discharge lipid levels are compatible with previous reports of changes in lipid levels during acute myocardial infarction. Total cholesterol has been reported to fall during the immediate post-infarction period, [2] [3] [4] [5] [6] [7] with the lowest levels occurring between the first and second weeks. 3, 5 Cholesterol levels appear to stabilize by about 2-3 months after the acute event. 2, 3, 5, 6 This likely reflects a return to the levels that existed prior to the MI. Lipid levels within the first 24-48 h after MI tend to be only minimally different from those before or more than 2 months after a myocardial infarction. In one study, total cholesterol levels determined within the first 24 h of hospitalization for acute MI were similar to those obtained 2 years before as well as 2 years after hospital discharge. 7 Although data on specific lipoproteins are limited, existing data are consistent with findings from the current study. The beta fraction (LDL) fell and the alpha fraction (HDL) increased within the first weeks after myocardial infarction in one study. 2 Triglyceride levels have been shown to fall within the first day and to rise to levels above those found on the initial measurement to a maximum at almost 3 weeks post-infarction. [4] [5] [6] From a practical standpoint, these observations have implications for clinicians caring for patients post-MI. The majority of patients admitted with an acute MI require intervention to lower cholesterol. This study was conducted in the early 1980s when the medical management of myocardial infarction may have had a different impact on lipids than today. Although not the primary hypothesis of this case-control study, its data on in-hospital and postdischarge lipid levels provided a unique opportunity to explore when decisions for lipid management based on NCEP guidelines may be made.
Doing an initial assessment in the hospital has several advantages. First, drawing the lipid profile in the hospital and determining the patient's degree of risk allows for early institution of therapy following myocardial infarction, which may have considerable advantages over a strategy that defers treatment decisions for weeks or even months. The long-term risks of reinfarction and CHD death have been shown to be increased in patients with high cholesterol post-MI, 14 and many authors have noted the highest mortality rates to be in the first 30 days to 6 months after MI. [15] [16] [17] [18] Further, quantitative angiographic trials [19] [20] [21] as well as recent randomized trials of HMG-CoA reductase inhibitors 22, 23 (CARE trial, personal communication) have suggested that benefits in terms of regression or even reduction in events may begin to accrue as soon as several months after the initiation of therapy. These early benefits of treatment may be important in reducing the high risks of morbidity and mortality in the first few months after MI, and might be lost if therapy were not instituted immediately. Moreover, the clinician may have the greatest impact in counseling a patient to make major dietary and lifestyle changes immediately after the acute illness, rather than waiting for the post-discharge office visit weeks to months later. Finally, immediately screening all patients in-hospital would reduce the risk of losing some to follow-up. We did not address whether particular patient characteristics may be more likely to lead to discrepant results when comparing inhospital and post-discharge lipid levels. Because the standard deviations for the mean differences in lipid levels were all considerably smaller than the lipid measurements at one point in time, few individuals exhibited such discrepant results.
Summary
There has been some reluctance to rely on lipid levels immediately following an MI, stemming from concerns that lipids change acutely after the event. It appears that despite these changes, in-hospital levels provide valuable information, especially if levels are assessed within 48 h of presentation with symptoms of an acute MI. It seems prudent that all patients admitted with the diagnosis of MI have a lipid profile measured prior to discharge, preferably within the first 48 h of hospitalization. While dietary and lifestyle recommendations seem appropriate for all MI patients, for those patients who meet NCEP criteria, pharmacologic interventions can begin immediately given the safety of these agents. For those with borderline elevations, repeat values should be obtained several weeks after discharge. These findings may also apply to those with clear coronary disease.
